SRC
GSK icon

Shufro Rose & Co’s GSK GSK Stock Holding History

Shufro Rose & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,794
Closed -$223K – 311
2024
Q3 		$223K Hold
5,794
– – 0.02% 275
2024
Q2 		$223K Buy
5,794
+630
+12% +$26.5K 0.02% 275
2024
Q1 		$221K Buy
+5,164
New +$213K 0.02% 267
2022
Q3 		– Sell
-4,854
Closed -$264K – 338
2022
Q2 		$264K Buy
+4,854
New +$268K 0.02% 238
2019
Q1 		– Sell
-7,000
Closed -$334K – 309
2018
Q4 		$334K Hold
7,000
– – 0.04% 196
2018
Q3 		$351K Sell
7,000
-720
-9% -$36.6K 0.03% 215
2018
Q2 		$389K Buy
7,720
+538
+7% +$27.1K 0.04% 195
2018
Q1 		$351K Hold
7,182
– – 0.03% 204
2017
Q4 		$318K Buy
7,182
+182
+3% +$8.41K 0.03% 213
2017
Q3 		$355K Buy
7,000
+1,200
+21% +$60.9K 0.04% 207
2017
Q2 		$313K Hold
5,800
– – 0.03% 201
2017
Q1 		$306K Buy
5,800
+600
+12% +$30.4K 0.03% 206
2016
Q4 		$250K Sell
5,200
-432
-8% -$21.3K 0.03% 218
2016
Q3 		$304K Hold
5,632
– – 0.03% 200
2016
Q2 		$305K Sell
5,632
-987
-15% -$52K 0.03% 192
2016
Q1 		$336K Buy
+6,619
New +$330K 0.04% 190

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Shufro Rose & Co's GSK Position: Q4 2024 in Review

Shufro Rose & Co sold out of GSK (GSK) in Q4 2024, closing a stake of 5,794 shares — an estimated $223K sold.

Shufro Rose & Co first reported a position in GSK in Q1 2016 and held it in 16 quarters. The position peaked at $389K in Q2 2018. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

  • Shufro Rose & Co reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
  • Shufro Rose & Co sold 5,794 GSK shares in Q4 2024, an estimated $223K.
  • Shufro Rose & Co first reported a position in GSK in Q1 2016 and held it in 16 quarters.
  • Shufro Rose & Co's GSK position peaked at $389K in Q2 2018.
  • 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Shufro Rose & Co's 13F filing for Q4 2024, filed 25 Feb 2025.